Document:

Document

Exhibit 10.2

August 28, 2020

Cynthia Gaylor 

Re: Offer of Employment

Dear Cynthia:

I am pleased to offer you a position with DocuSign, Inc. (the “Company”) as Chief Financial Officer, based in our San Francisco office, reporting to me, expected to commence on the date that is one business day after the Company files its quarterly report on Form 10-Q for the quarter ended July 31, 2020 (the “Start Date”), anticipated to be on or about September 8, 2020.

The Company acknowledges receipt of your resignation letter confirming your resignation from the Audit Committee of the Company’s Board of Directors (the “Board”), effective immediately, and your resignation from the Board, effective immediately following your commencement of employment on the Start Date.

You will receive a salary of $460,000 per year less applicable taxes and deductions, which will be paid biweekly in accordance with the Company’s normal payroll procedures. In addition, you will be eligible for a target bonus equal to 50% of your eligible compensation, subject to the terms and conditions of the Company Incentive Plan (“CIP”) in effect for each applicable fiscal year. The CIP plan document contains important information including eligibility, pro-ration for employees on a leave of absence or hired mid-year, and the measures used to track Company’s achievement of targets for the plan year as established by management, the Board, or a committee appointed by the Board. If your employment starts December 1st or later of a specific fiscal year, your first eligibility to participate in the CIP will not be until the following fiscal year.

In addition, subject to the sole discretion of the Company and based on your individual and the Company’s performance, you will also be eligible to be recommended for a discretionary focal equity grant in calendar year 2021, following the completion of your focal review for fiscal 2021.

Subject to approval of the Board, or a committee appointed by the Board, you will be eligible to receive an award of RSUs representing the right to acquire shares of Common Stock of DocuSign, Inc. with a target value of $11,000,000.00. The number of RSUs you receive will be determined by dividing the target value by the average closing stock price over a period of 10 trading days immediately prior to the Vesting Commencement Date. The Vesting Commencement Date will be the first 10th day of a month following your Start Date. Such RSUs will be subject to the terms and conditions of: (a) the Company’s equity incentive program in effect at the time of grant (the “Plan”), (b) an RSU Agreement, as applicable, in the form approved by the Board or a committee of the Board, and (c) applicable law. The RSUs will be subject to service-based requirements as set forth in the RSU Agreement. For a general summary of the vesting terms, please see Attachment A hereto.

As a Company employee, you will also be eligible to receive certain employee benefits including PTO, healthcare, dental coverage, and a 401(k) plan. You should note that the Company may modify salaries and benefits from time to time as it deems necessary. You should be aware that your employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason.

Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without notice. The Company reserves the right to conduct background investigations and/or reference checks on all of its potential employees. Your job offer, therefore, is contingent upon a clearance of such a background investigation and/or reference check, if any. Please 

note your Start Date is subject to change if your background check has not been completed by Monday of the week prior to your Start Date.

For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three business days of your date of hire, or our employment relationship with you may be terminated. If you require work authorization to lawfully work in the U.S., this must be obtained prior to your State Date and your Start Date is subject to change if proof of such authorization is not obtained by the Company by Monday of the week prior to your Start Date.

You agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company.

Severance and Change In Control. Subject to approval of the Board, or a committee appointed by the Board, you will also be eligible to participate in the Executive Severance and Change in Control Plan (the "CIC Plan") attached as Attachment B hereto; provided that the definition of Good Reason in Exhibit A of the CIC Plan shall be deemed amended in its entirety to read as follows:

“Good Reason” for Executive’s resignation of employment will exist following the occurrence of any of the following without Executive’s express written consent:

(i) a material reduction in Executive’s duties or responsibilities without Executive’s consent, provided that neither a change in title, nor a change in Executive’s reporting relationships by virtue of the Company being acquired or made part of a larger entity (as, for example, where the Company becomes a subsidiary or operating unit of the acquiring corporation following a Change in Control) will be deemed a “material reduction” in and of itself unless Executive’s new duties and responsibilities are materially reduced from the prior duties and responsibilities;
(ii) a material reduction in Executive’s base compensation, unless such reduction is made in connection with a similar action affecting all senior executives; or
(iii) a relocation of Executive’s principal place of employment to a place that increases Executive’s one-way commute by more than thirty (30) miles as compared to Executive’s then- current principal place of employment immediately prior to such relocation.

In order to resign for Good Reason, Executive must provide written notice to Board within 90 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive’s resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, Executive must resign from all positions Executive then holds with the Company not later than 30 days after the expiration of the cure period.

Board Equity Grants
Your commencement of employment on the Start Date will constitute “Continuous Service” for purposes of the restricted stock units (“RSUs”) previously awarded to you in your capacity as a member of the Board (your “Board Service Equity Awards”), which will continue to vest according to their terms following the Start Date (except as set forth below with respect to acceleration).

Notwithstanding anything to the contrary in the Non-Employee Director Compensation Policy, as amended and restated on May 29, 2020 (the “Director Compensation Policy”), any Company equity incentive plan or the equity award agreements governing your Board Service Equity Awards, such Board Service Equity Awards will no longer be entitled to accelerated vesting upon a Change in Control or upon a termination of service, and instead any Board Service Equity Awards will only be eligible for accelerated vesting pursuant to the CIC Plan.

Section 409A. All amounts paid under this letter, including the Severance and Change in Control Benefits provided in Attachment B, shall be paid less all applicable state and federal tax withholdings (if any) and any other withholdings required by any applicable jurisdiction or authorized by you. Notwithstanding any other provision of this letter whatsoever, the Company, in its sole discretion, shall have the right to provide for the application and effects of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (relating to deferred compensation arrangements) and any related administrative guidance issued by the Internal Revenue Service. The Company shall have the authority to delay the payment of any amounts under this Agreement to the extent it deems necessary or appropriate to comply with Section 409A(a)(2)(B)(i) of the Code (relating to payments made to certain “specified employees” of publicly-traded companies); in such event, any such amount to which you would otherwise be entitled during the six (6) month period immediately following your termination of employment with the Company will be paid in a lump sum on the date six (6) months and one (1) day following the date of your termination of employment with the Company (or the next business day if such date is not a business day), provided that you have complied with the requirements for such payment. You shall be treated as having a termination of employment under this Agreement only if such termination meets the requirements of a “separation from service” as that term is defined in Section 409A(a)(2)(A)(i) of the Code and Treas. Regs. Section 1.409A-1(h), and as amplified by any other official guidance. This letter agreement is intended to comply with the provisions of Code Section 409A; provided, however, that the Company makes no representation that the amounts payable under this letter will comply with Code Section 409A and makes no undertaking to prevent Code Section 409A from applying to amounts payable under this letter or to mitigate its effects on any deferrals or payments made under this letter.

Company Policies. As a Company employee, you will be expected to abide by company rules and regulations. You will be specifically required to sign an acknowledgment that you have read and understand the company rules of conduct which are included in the employee handbook which you will receive on your first day of employment. You will be expected to sign and comply with an Employment Confidential Information, Invention Assignment and Arbitration Agreement which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company and non-disclosure of proprietary information. The Agreement also provides that in the event of any dispute or claim relating to or arising out of our working relationship, you and the Company agree that all such disputes shall be resolved by binding arbitration.

To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below by 5:00 p.m. Pacific time on August 30, 2020. This letter, along with the agreements and plans incorporated by reference herein, set forth the terms of your employment with the Company and supersede any prior representations or agreements, whether written or oral. This letter may not be modified or amended except by a written agreement, signed by an officer of the Company and by you.

We look forward to working with you at DocuSign, Inc.

Sincerely,
DocuSign, Inc.

 /s/ Daniel Springer    
Dan Springer, CEO
ACCEPTED AND AGREED:

Cynthia Gaylor

/s/ Cynthia Gaylor  
Signature

Attachment A

RSU Vesting Terms

As provided in more detail in the RSU Agreement, your RSUs will become “Vested RSUs” subject to the satisfaction of a service-based requirement. Generally, 25% of the total number RSUs awarded will have the service-based requirement satisfied on the 12-month anniversary of the vesting commencement date, and thereafter 1/16th of the total number of RSUs awarded will have the service-based requirement satisfied in a series of 12 successive equal quarterly installments following the first anniversary of the vesting commencement date until the service- based requirement is fully satisfied on the fourth anniversary of the vesting commencement date, subject to your continued employment or service with the Company on each such date.

Vested RSUs will generally be delivered to you (“settled”) on a quarterly basis (March, June, September and December).

The RSUs will be subject to the terms and conditions of the Plan and the applicable RSU Agreement.

Attachment B

DOCUSIGN, INC.
EXECUTIVE SEVERANCE AND CHANGE IN CONTROL PLAN

This Executive Severance and Change in Control Plan (the “Agreement”) by and between the undersigned executive (“Executive”) and DocuSign, Inc., a Delaware corporation (the “Company”) is effective on the Executive’s start date as an employee of the Company.

RECITALS

A. The Company’s Board of Directors (the “Board”) believes it is in the best interests of the Company and its stockholders to hire Executive and to provide Executive with certain protections in the event of Executive’s termination of employment or a Change in Control of the Company under certain circumstances.

B. To accomplish the foregoing objectives, the Board has directed the Company, upon execution of this Agreement by Executive, to agree to the terms provided in this Agreement. Capitalized terms not defined below shall have the meanings set forth in Exhibit A or Exhibit B, as applicable.

AGREEMENT

The parties hereto agree as follows:

1. At-Will Employment. Nothing in this Agreement alters the at-will nature of Executive’s employment. Executive and the Company remain free to terminate the employment relationship at any time, for any reason, with or without notice.

2. Benefits Upon Qualifying Termination Outside the Change in Control Period. Upon Executive’s Qualifying Termination outside a Change in Control Period, and subject to the conditions in Section 4, the Company will provide Executive with the following severance benefits:

a. Severance Pay. The Company will pay Executive a lump sum cash payment, less all applicable withholdings and deductions, in an amount equal to:

i. 6 months of Executive’s then-current base salary (ignoring any decrease in base salary that forms the basis for Good Reason); and

ii. 50% of Executive’s target annual bonus for the performance year in which the Qualifying Termination occurs.

b. Continued Health Insurance Coverage. Provided Executive timely elects COBRA continuation coverage, the Company will pay the COBRA premiums to continue and maintain health care coverage for Executive and any dependents who are covered at the time of the Executive’s termination of employment under the Company’s group health plans. The Company will make such payments until the earliest of: (i) 6 months following the Qualifying Termination date; (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law, the Company may pay Executive a taxable cash payment equal to the amount that the Company would have otherwise paid for COBRA premiums (based on the premium for the first month of 

coverage), which payment will be made regardless of whether Executive or Executive’s eligible dependents elect COBRA continuation coverage and will be paid in monthly installments on the same schedule and over the same time period that the COBRA premiums would otherwise have been paid on behalf of Executive.

c. Equity Vesting Acceleration. The vesting of each of Executive’s then- outstanding equity compensation awards (other than Performance Awards (as defined below) granted under any of the Company’s equity incentive plans will accelerate as to the number of shares subject to each such award that would have become vested, in the ordinary course, within the first 6 months following Executive’s termination date, effective on Executive’s date of termination. With respect to awards that would otherwise vest only upon satisfaction of performance criteria (“Performance Awards”), then the vesting of such awards will accelerate as set forth in the terms of the applicable performance-based equity award agreement. [For purposes of clarity, if any restricted stock unit award that Executive holds contains a condition requiring the occurrence of a liquidity event (such as an initial public offering or a change in control) as a condition to settlement, this accelerated vesting provision will not result in a waiver of such liquidity event condition, but will apply to any separate service-based vesting requirement contained in the award.

Subject to the payment timing rules contained in Exhibit B, any severance payments and benefits under this Section 2 will be paid on the later of (x) 10 business days after the effective date of the Release and (y) the date of Executive’s Qualifying Termination.

3. Qualifying Termination During the Change in Control Period. Upon Executive’s Qualifying Termination during the Change in Control Period, and subject to the conditions in Section 4, the Company will provide Executive with he following severance benefits:
a. Severance Pay. The Company will pay Executive a lump sum cash payment, less all applicable withholdings and deductions, in an amount equal to:

i. 12 months of Executive’s then-current base salary (ignoring any decrease in base salary that forms the basis for Good Reason); and

ii. No target annual bonus for the performance year in which the Qualifying Termination occurs (this means no pro rata or partial annual bonus payment will be owed).

b. Continued Health Insurance Coverage. Provided Executive timely elects COBRA continuation coverage, the Company will pay the COBRA premiums to continue and maintain health care coverage for Executive and any dependents who are covered at the time of the Executive’s termination of employment under the Company’s group health plans. The Company will make such payments until the earliest of: (i) 12 months following the Qualifying Termination date; (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law, the Company may pay Executive a taxable cash payment equal to the amount that the Company would have otherwise paid for COBRA premiums (based on the premium for the first month of coverage), which payment will be made regardless of whether Executive or Executive’s eligible dependents elect COBRA continuation coverage and will be paid in monthly installments on the same schedule and over the same time period that the COBRA premiums would otherwise have been paid on behalf of Executive.

c. The vesting of each of Executive’s then-outstanding compensatory equity awards (other than Performance Awards) granted under any of the Company’s equity incentive plans will 

accelerate in full. With respect to Performance Awards, the vesting of such awards will accelerate as set forth in the terms of the applicable performance-based equity award agreement. In order to accommodate this potential accelerated vesting, if Executive experiences a Qualifying Termination within 90 days prior to a Change in Control, any then-unvested compensatory equity awards will not terminate with respect to shares that have not vested as of Executive’s termination date until 6 months and one day after Executive’s termination date.

Subject to the payment timing rules contained in Exhibit B, any severance payments and benefits under this Section 3 will be paid on the latest of (x) 10 business days after the effective date of the Release, (y) the date of Executive’s Qualifying Termination, and (z) the date of the Change in Control.
4. Limitations and Conditions on Termination Benefits

a. Release Prior to Payment of Benefits. In order to be eligible to receive any benefits under Sections 2 or 3, Executive must (i) execute and return a general waiver and release, in a form provided by the Company and reasonably acceptable to Executive, of all employment related obligations of and claims and causes of action against the Company (a “Release”), to the Company within the applicable time period set forth therein and (ii) not revoke the Release within the revocation period (if any) set forth therein; provided, however, that in no event may the applicable time period or revocation period extend beyond sixty (60) days following Executive’s termination date.

b. Income and Employment Taxes. Executives agrees that Executive will be responsible for any applicable taxes of any nature (including any penalties or interest that may apply to such taxes) that the Company reasonably determines apply to any payment made hereunder, that Executive’s receipt of any benefit hereunder is conditioned on Executive’s satisfaction of any applicable withholding or similar obligations that apply to such benefit, and that any cash payment owed hereunder will be reduced to satisfy any such withholding or similar obligations that may apply.

c. Related Matters. Executive further acknowledges and agrees that as a condition to receipt of any severance benefits, Executive must (i) comply with Executive’s obligations under Executive’s At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement; and (ii) resign from all officer and director positions with the Company and/or any affiliate (unless otherwise requested by the Company).

d. Section 409A and Section 280G. Executive and the Company understand that payments under this Agreement may be subject to Sections 409A and 280G of the Code, and the parties agree to abide by the Section 409A and Section 280G provisions contained in Exhibit B to this Agreement.

5. Miscellaneous Provisions.

a. Interaction with Other Benefits. In the event that Executive would be entitled to a greater level of payments or benefits under the terms and conditions of an individual equity compensation award, offer letter or other employment-related agreement, or a severance plan or policy provided by the Company or its successor, but for the existence of this Agreement, Executive shall be entitled to receive the greater of the payments and benefits provided for hereunder or the benefits under such other agreement, plan or policy subject to the applicable terms and conditions thereof.

b. Complete Agreement. This Agreement supersedes any agreement (or portion thereof) concerning similar subject matter dated prior to the date of this Agreement, and by execution of this Agreement both parties agree that any such predecessor agreement (or portion 

thereof) shall be deemed null and void; provided that, for clarification purposes, this Agreement shall not affect any agreement between the Company and Executive regarding intellectual property matters, non-solicitation or non- competition restrictions or confidential information. The parties further agree that this Agreement does not supersede the provisions of Executive’s offer letter or employment agreement with the Company which do not address termination or severance benefits or Executive’s At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement.

c. Waiver. No provision of this Agreement may be waived unless the waiver is agreed to in writing and signed by Executive and by an authorized officer of the Company. No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement shall be considered a waiver at another time.

d. Successors and Assigns. This Agreement is personal to Executive and will not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns. From and after a Change in Control, the term “Company” when used in this Agreement will also be read to include any entity that actually employs Executive, if different from the Company.

e. Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California without reference to conflict of laws provisions, and the parties hereto submit to the exclusive jurisdiction of the state and federal courts of the State of California.

f. Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.

g. Notice. Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. Mailed notices to Executive shall be addressed to Executive at the home address which Executive most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of the Board.

h. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument, and facsimile and electronic signatures shall be equivalent to original signatures.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date written below.

Company:
DocuSign, Inc.

By:  /s/ Daniel Springer    
Dan Springer, CEO
Executive:
Cynthia Gaylor

By: /s/ Cynthia Gaylor  
Date: August 31, 2020 

Exhibit A
Definitions

“Cause” will mean the occurrence of one or more of the following:

(i) Executive’s willful and continued failure to perform the duties and responsibilities of Executive’s position after there has been delivered to Executive a written demand for performance from the Company which describes the basis for the Company’s belief that Executive has not substantially performed Executive’s duties and provides Executive with thirty (30) days to take corrective action;
(ii) any act of personal dishonesty taken by Executive in connection with Executive’s responsibilities as an employee of the Company with the intention or reasonable expectation that such action may result in substantial personal enrichment of Executive;
(iii) Executive’s conviction of, or plea of nolo contendere to, a felony;
(iv) Executive’s commission of any tortious act, unlawful act or malfeasance which causes or reasonably could cause (for example, if it became publicly known) material harm to the Company’s standing, condition or reputation;
(v) any material breach by Executive of the provisions of the At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement or other improper disclosure of the Company’s confidential or proprietary information;
(vi) a breach of any fiduciary duty owed to the Company by Executive that has or could reasonably be expected to have a material detrimental effect on the Company’s reputation or business; or
(vii) Executive (A) obstructing or impeding; (B) endeavoring to influence, obstruct or impede, or (C) failing to materially cooperate with, any investigation authorized by the Board or any governmental or self-regulatory entity (an “Investigation”). However, Executive’s failure to waive attorney-client privilege relating to communications with Executive’s own attorney in connection with an Investigation will not constitute “Cause.”

“Change in Control” will have the meaning set forth in the Company’s Amended and Restated 2018 Equity Incentive Plan.

“Change in Control Period” means the period beginning 90 days prior to and ending on the 24- month anniversary of the effective date of a Change in Control.

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended together with any analogous provisions of applicable state law.

“Code” means Internal Revenue Code of 1986, as amended, and the Treasury regulations and formal guidance promulgated thereunder, each as may be amended or modified from time to time.

“Good Reason” for Executive’s resignation of employment will exist following the occurrence of any of the following without Executive’s express written consent:
(i) a material reduction in Executive’s duties or responsibilities without Executive’s consent, provided that neither a change in title, nor a change in Executive’s reporting relationships by virtue of the Company being acquired or made part of a larger entity (as, for example, where the Company becomes a subsidiary or operating unit of the acquiring corporation following a Change in Control) will be deemed a “material reduction” in and of itself unless Executive’s new duties and responsibilities are materially reduced from the prior duties and responsibilities;
(ii) a material reduction in Executive’s base compensation, unless such reduction is made in connection with a similar action affecting all senior executives; or

(iii) a relocation of Executive’s principal place of employment to a place that increases Executive’s one-way commute by more than fifty (50) miles as compared to Executive’s then-current principal place of employment immediately prior to such relocation.

In order to resign for Good Reason, Executive must provide written notice to Board within 90 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive’s resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, Executive must resign from all positions Executive then holds with the Company not later than 30 days after the expiration of the cure period.
“Qualifying Termination” shall mean the termination of Executive’s employment by the Company without Cause or by Executive with Good Reason.

“Qualifying Termination” shall mean the termination of Executive’s employment by the Company without Cause or by Executive with Good Reason.

Exhibit B
SECTION 409A AND SECTION 280G MATTERS

1. Section 409A

It is intended that the Agreement shall comply with the requirements of Section 409A of the Code, and any payments hereunder are intended to be exempt from, or if not so exempt, to comply with the requirements of Section 409A of the Code, and this Agreement shall be interpreted, operated and administered accordingly. To the extent that any provision of the Agreement is ambiguous, but a reasonable interpretation of the provision would cause any payment or benefit to comply with or be exempt from the requirements of Section 409A of the Code, Executive and the Company intend the term to be interpreted as such in order to avoid adverse personal tax consequences under Section 409A.

No severance or other payments or benefits otherwise payable to Executive upon a termination of employment under the Agreement or otherwise will be payable until Executive has a “separation from service” as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder.

If the period during which Executive may sign the Release begins in one calendar year and ends in the following calendar year, then no severance payments or benefits that that would constitute deferred compensation within the meaning of Section 409A of the Code will be paid or provided until the later calendar year.

The severance payments and benefits under the Agreement are intended to satisfy the exemptions from application of Section 409A of the Code provided under Treasury Regulations Sections 1.409A- 1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and Executive is a “specified employee” within the meaning of Section 409A of the Code at the time of Executive’s separation from service, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code, any payments payable under the Agreement on account of a separation from service that would constitute deferred compensation within the meaning of Section 409A of the Code and that would (but for this provision) be payable within 6 months following the date of termination, shall instead be paid on the next business day following the expiration of such six month period or, if earlier, upon Executive’s death. Each installment payment under the Agreement is a “separate payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i).

2. Section 280G

If any payment or benefit (including payments and benefits pursuant to the Agreement) that Executive would receive in connection with a Change in Control from the Company or otherwise (a “Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to Executive, which of the following two alternative forms of payment would result in Executive’s receipt, on an after-tax basis, of the greater amount of Transaction Payments notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (1) payment in full of the entire amount of the Transaction Payments (a “Full Payment”), or (2) payment of only a portion of the Transaction Payments so that Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”). For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state, local and foreign income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (x) Executive shall have no rights to any additional payments and/or benefits constituting the forfeited 

portion of the Full Payment, and (y) reduction in payments and/or benefits will occur in the manner that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. Notwithstanding the foregoing, if such reduction would result in any portion of the Transaction Payments being subject to penalties pursuant to Section 409A that would not otherwise be subject to such penalties, then the reduction method shall be modified so as to avoid the imposition of penalties pursuant to Section 409A as follows: (A) Transaction Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Transaction Payments that are not contingent on future events; and (B) Transaction Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Transaction Payments that are not deferred compensation within the meaning of Section 409A. In the event that acceleration of vesting of any equity compensation awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of Executive’s equity awards. In no event will the Company or any stockholder be liable to Executive for any amounts not paid as a result of the operation of this provision.

The professional firm engaged by the Company for general tax purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Exhibit B. If the professional firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such professional firm required to be made hereunder

The professional firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within a reasonable period after the date on which Executive’s right to a Transaction Payment is triggered or such other time as reasonably requested by the Company or Executive. If the professional firm determines that no Excise Tax is payable with respect to the Transaction Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with detailed supporting calculations of its determinations that no Excise Tax will be imposed with respect to such Transaction Payment. Any good faith determinations of the professional firm made hereunder shall be final, binding and conclusive upon the Company and Executive.

Notwithstanding the foregoing, if the Company is privately held as of immediately prior to a Change in Control and it is deemed necessary by the Company to avoid any potential imposition of the adverse tax results provided for by Sections 280G and 4999 of the Code, then as a further condition to any payment or benefit provided for in the Agreement or otherwise, the Company may require Executive to submit any payment or benefit provided for in the Agreement or from any other source that the Company reasonably determines may constitute an “excess parachute payment” (as defined in Section 280G(b)(1) of the Code) for approval by the Company’s stockholders prior to the Closing of the Change in Control in the manner required by the terms of Section 280G(b)(5)(B) of the Code, so that no payments or benefits will be deemed to constitute a “parachute payment” subject to the excise taxes under Sections 280G and 4999 of the Code.EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 SEAGATE HDD
CAYMAN 
 3.125% SENIOR NOTES DUE 2029 

3.375% SENIOR NOTES DUE 2031 

PURCHASE AGREEMENT 
 December 3, 2020 

 December 3, 2020 

Morgan Stanley & Co. LLC 
 1585 Broadway 

New York, New York 10036 
 Ladies and Gentlemen: 

Seagate HDD Cayman, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the
“Issuer”), proposes to issue and sell to the several purchasers named in Schedule I hereto (the “Initial Purchasers”) $500,000,000 principal amount of its 3.125% Senior Notes due 2029 (the “2029
Notes”) and $500,000,000 principal amount of its 3.375% Senior Notes due 2031 (the “2031 Notes,” together with the 2029 Notes, the “Notes”). The 2029 Notes will be issued pursuant to the provisions
of an Indenture, to be dated on or about December 8, 2020 (the “2029 Indenture”) among the Issuer, the Company (as defined below) and Wells Fargo Bank, National Association, a national banking association, as Trustee (in such
capacity, the “Trustee”) and the 2031 Notes will be issued pursuant to the provisions of an Indenture, to be dated on or about December 8, 2020 (the “2031 Indenture” together with the 2031
Indenture, the “Indentures”) among the Issuer, the Company (as defined below) and Trustee. 
 The
Notes will be unconditionally guaranteed (the “Guarantee,” and together with the Notes, the “Securities”) as to the payment of principal and interest by Seagate Technology plc, a public limited company incorporated
under the laws of Ireland (the “Company”). 
 The Securities will be offered without being registered under the Securities
Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in compliance with the exemption from registration provided by Rule 144A under the Securities Act (“Rule 144A”) and in offshore
transactions in reliance on Regulation S under the Securities Act (“Regulation S”). 
 The Initial
Purchasers of the Securities and their direct and indirect transferees will be entitled to the benefits of Registration Rights Agreements in respect of the Securities for each series of Notes, each dated the Closing Date (as defined herein), between
the Issuer, the Company and the Initial Purchasers (the “2029 Registration Rights Agreement” together with the “2031 Registration Rights Agreement” the “Registration Rights
Agreements” ). 

 In connection with the sale of the Securities, the Issuer has prepared a preliminary
offering memorandum (the “Preliminary Memorandum”) and will prepare a final offering memorandum (the “Final Memorandum”) including or incorporating by reference a description of the terms of the Securities, the
terms of the offering and a description of the Issuer and the Company. For purposes of this Agreement, “Additional Written Offering Communication” means any written communication (as defined in Rule 405 under the Securities Act)
that constitutes an offer to sell or a solicitation of an offer to buy the Securities other than the Preliminary Memorandum or the Final Memorandum, and “Time of Sale Memorandum” means the Preliminary Memorandum together with the
Additional Written Offering Communications, if any, each identified in Schedule II hereto; and “General Solicitation” means any offer to sell or solicitation of an offer to buy the Securities by any form of general solicitation or
advertising (as those terms are used in Regulation D under the Securities Act). As used herein, the terms Preliminary Memorandum, Time of Sale Memorandum and Final Memorandum shall include the documents, if any, incorporated by reference therein.
The terms “supplement,” “amendment” and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or any Additional Written Offering
Communication shall include all documents subsequently filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), that are deemed to be incorporated by reference therein. 
 1. Representations and Warranties. Each of the Issuer and
the Company, jointly and severally, represent and warrant to, and agree with, you that: 
 (a) the Time of Sale Memorandum
does not contain, and (x) at the time of first sale of the Securities and (y) at the Closing Date (as defined in Section 4), the Time of Sale Memorandum, as then amended or supplemented by the Company, if applicable, will not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, any Additional Written Offering Communication prepared,
used or referred to by the Company, when considered together with the Time of Sale Memorandum, at the time of its use did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, any General Solicitation that is not an Additional Written Offering Communication, made by the Issuer or the Company or by the Initial Purchaser with the consent of the
Issuer and the Company, when considered together with the Time of Sale Memorandum, at the time when made or used did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading, and the 

  
 2 

 
Preliminary Memorandum as of its date did not contain and the Final Memorandum, in the form used by the Initial Purchasers to confirm sales and on the Closing Date (as defined in Section 4),
will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however that the
representations and warranties set forth in this paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, Additional Written Offering Communication or General Solicitation
based upon information relating to any Initial Purchaser furnished to the Company or the Issuer in writing by such Initial Purchaser through you expressly for use therein. 

(b) Except for the Additional Written Offering Communications, if any, identified in Schedule II hereto, and electronic road
shows, if any, furnished to you before first use, neither the Company nor the Issuer have prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any Additional Written Offering Communication. 

(c) The Company has been duly incorporated, is validly existing as a public limited company under the laws of Ireland, has the
corporate power and authority to own its property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and, except in jurisdictions in which “good standing” is not a recognized
concept, is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified would not have a material adverse
effect on the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”). 
 (d) Each
subsidiary of the Company has been duly organized, is validly existing as a corporation, limited liability company or other similar entity under the laws of the jurisdiction of its organization, has the corporate power and authority to own its
property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is in good standing, except in jurisdictions in which “good standing” is not a recognized concept, in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect; all of
the issued share capital of each subsidiary of the Company has been duly and validly authorized and issued, are 

  
 3 

 
fully paid and non-assessable and (except for directors’ qualifying shares) are directly or indirectly owned by the Company, free and clear of all
liens, encumbrances, equities or claims (each, a “Lien”), except for Liens as described in the Time of Sale Memorandum and the Final Memorandum. 

(e) This Agreement has been duly authorized, executed and delivered by the Issuer and the Company. 

(f) The Notes have been duly authorized and, when executed and authenticated in accordance with the provisions of the
Indentures and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid and binding obligations of the Issuer, enforceable in accordance with their terms, subject to applicable bankruptcy,
insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability, and will be entitled to the benefits of the relevant Indenture pursuant to which such Securities are to be issued. 

(g) The Guarantees contained in the Indentures have been, or will be as of the Closing Date, duly authorized by the Company,
and when the Notes are executed and authenticated in accordance with the provisions of the relevant Indenture, and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, each Guarantee will be the valid
and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general
applicability, and will be entitled to the benefits of the relevant Indenture. 
 (h) The execution and delivery by the
Issuer and the Company of, and the performance by the Issuer and the Company of their obligations under, this Agreement, the Indentures, the Registration Rights Agreements (collectively, the “Transaction Documents”) and the
Securities will not contravene the memorandum and articles of association, constitution, charter, by-laws or other organizational documents of the Issuer or the Company or any agreement or other instrument
binding upon the Issuer or the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, contravene any provision of applicable law or any judgment, order or decree of any governmental body, agency or
court having jurisdiction over the Company or any subsidiary (except for such contraventions of applicable law or judgments that would not reasonably be expected to have a Material Adverse Effect or a material adverse

  
 4 

 
effect on the power or ability of the Issuer and the Company to perform their respective obligations under the Transaction Documents or the Securities) or result in the imposition or creation of
(or the obligation to create or impose) a Lien under, any agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries or their respective property is bound; no consent,
approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Issuer or the Company of their respective obligations under the Transaction Documents, except such as (i) may be
required by the securities or Blue Sky laws of the various states or other jurisdictions in connection with the offer and sale of the Securities, or (ii) the failure of which to obtain would not reasonably be expected to have a material adverse
effect on the power or ability of the Issuer or the Company to perform their respective obligations under the Transaction Documents and the Securities. 

(i) The Indentures have been duly authorized by the Issuer and the Company, and when duly executed and delivered by the Issuer
and the Company, assuming the due authorization, execution and delivery thereof by the other parties thereto, will each constitute a valid and binding agreement of the Issuer and the Company, enforceable against the Issuer and the Company in
accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability. 

(j) The Registration Rights Agreements have been duly authorized by the Issuer and the Company, and when duly executed and
delivered by the Issuer and the Company, assuming the due authorization, execution and delivery thereof by the other parties thereto, will each constitute a valid and binding agreement of the Issuer and the Company, enforceable against the Issuer
and the Company in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability and except as rights to indemnification and
contribution may be limited under applicable law. 
 (k) There has been no material adverse change, nor to the knowledge of
the Company, any development involving a prospective material adverse change, in the financial condition or in the earnings, business affairs or management of the Company and its subsidiaries, taken as a whole, whether or not arising in the ordinary
course of business from that set forth in or contemplated by the Time of Sale Memorandum. 

  
 5 

 (l) Other than as described in the Time of Sale Memorandum and the Final
Memorandum, there are no legal or governmental actions, suits or proceedings pending or, to the Company’s knowledge, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any
of its subsidiaries is subject that would have a Material Adverse Effect or a material adverse effect on the power or ability of the Issuer or the Company to perform their respective obligations under the Transaction Documents or the Securities or
to consummate the transactions contemplated by the Time of Sale Memorandum. 
 (m) The financial statements included or
incorporated by reference in the Time of Sale Memorandum present fairly in all material respects the financial position of the entities purported to be covered as of the dates shown and their results of operations and cash flows for the periods
shown, and such financial statements have been prepared in conformity with the generally accepted accounting principles in the United States applied on a consistent basis (except as otherwise noted therein). 

(n) Neither the Company nor the Issuer is, nor after giving effect to the offering and sale of the Securities and the
application of the proceeds thereof as described in the Final Memorandum will be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 

(o) The Company and its subsidiaries are in compliance with any and all applicable
non-U.S., and U.S. federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(“Environmental Laws”), have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and are in compliance with all terms and conditions of any
such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals
would not, singly or in the aggregate, have a Material Adverse Effect. 
 (p) Except as described in the Time of Sale
Memorandum and the Final Memorandum, there are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of
properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a Material Adverse
Effect. 

  
 6 

 (q) Neither the Company nor any of its subsidiaries or, to the
Company’s knowledge, any director, officer, employee or any agent of the Company or of any of its subsidiaries, has given money or anything else of value, directly or indirectly, to a “government official” (including any officer or
employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office) to influence official action or secure an improper advantage; and the Company and its subsidiaries have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintain and will
continue to maintain policies and procedures designed to promote and achieve compliance with such laws. 
 (r) The operations
of the Company and its subsidiaries are and have been conducted in material compliance with all applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws that would reasonably be expected to have a Material Adverse Effect is pending or, to the
knowledge of the Company, threatened. 
 (s) Neither the Company nor any of its subsidiaries or, to the Company’s
knowledge, any director, officer, employee or agent of the Company or of any of its subsidiaries, is, or is owned or controlled by an individual or entity (“Person”) that is: currently the subject of any sanctions administered or
enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”) or Her Majesty’s Treasury
(“HMT”) (collectively, “Sanctions”), nor located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the Crimea Region, Cuba, Iran, North Korea and
Syria) and the Company, including its subsidiaries, represents and warrants that it will not, directly or indirectly, use the proceeds from 

  
 7 

 
the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiary or other Person, to fund or facilitate any activities or business of or with any Person
or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions. 
 (t)
Subsequent to the respective dates as of which information is given in each of the Time of Sale Memorandum and the Final Memorandum, (i) neither the Company nor any of its subsidiaries have incurred any material liability or obligation, direct
or contingent, nor entered into any material transaction not in the ordinary course of business; (ii) neither the Issuer nor the Company has purchased any of its outstanding share capital, nor declared, paid or otherwise made any dividend or
distribution of any kind on its share capital other than ordinary and customary dividends; and (iii) there has not been any material change in the share capital, capital stock or long-term debt of the Company and its subsidiaries, except in the
case of each of (i), (ii), and (iii) above, as described in, or contemplated by, each of the Time of Sale Memorandum and the Final Memorandum and in the case of purchases of or changes in share capital, pursuant to the Company’s ongoing
share repurchase program described in each of the Time of Sale Memorandum and the Final Memorandum, respectively. 
 (u) The
Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case
free and clear of all Liens, except such as are described in the Time of Sale Memorandum and the Final Memorandum or such as do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries
or such as would not reasonably be expected to have a Material Adverse Effect; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Time of Sale Memorandum and the Final
Memorandum. 
 (v) Except as described in the Time of Sale Memorandum and the Final Memorandum, the Company and its
subsidiaries own or possess a valid right to use, or can acquire on reasonable terms, all material patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other
unpatented and/or unpatentable 

  
 8 

 
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, domain names and other intellectual property currently employed by them in connection with
the operation of the business as currently operated by them, and neither the Company nor any of its subsidiaries, to the knowledge of the Company, has received any notice of infringement of or conflict with asserted rights of others with respect to
any of the foregoing which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect. 

(w) (i) The Company and its subsidiaries use and have used any and all software and other materials distributed under a
“free,” “open source,” or similar licensing model (including but not limited to the MIT License, Apache License, GNU General Public License, GNU Lesser General Public License and GNU Affero General Public License) (“Open
Source Software”) in compliance with all license terms applicable to such Open Source Software, except where the failure to comply would not reasonably be expected to result in a Material Adverse Effect; and (ii) to the knowledge of
the Company neither the Company nor any of its subsidiaries uses or distributes or has used or distributed any Open Source Software in any manner that requires (A) the Company or any of its subsidiaries to permit reverse engineering of any
software code or technology owned by the Company or any of its subsidiaries and intended to be kept as proprietary software or (B) any software code or other technology owned by the Company or any of its subsidiaries and intended to be kept as
proprietary to be (1) disclosed or distributed in source code form, (2) licensed for the purpose of making derivative works or (3) redistributed at no charge, except as would not reasonably be expected to result in a Material Adverse
Effect. 
 (x) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect, (i) the Company and each of its subsidiaries have complied and are presently in compliance with all of their internal and external privacy policies, contractual obligations relating to privacy, data protection, or information security,
and applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority, in each case, relating to privacy, data protection, and information security with respect to the
collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personal, personally identifiable, household or sensitive data considered “personal information” or
“personal data” under applicable laws and regulations (“Data Security Obligations”, and such data, “Data”); (ii) the Company has not received any written notification

  
 9 

 
of or complaint regarding the non-compliance of the Company or any of its subsidiaries with any Data Security Obligation; and (iii) there is no
action, suit or proceeding by or before any court or governmental agency, authority or body pending or threatened in writing against the Company or its subsidiaries alleging non-compliance with any Data
Security Obligation. 
 (y) Except as would not, individually or in the aggregate, reasonably be expected to result in a
Material Adverse Effect, (i) the Company and each of its subsidiaries have taken reasonable technical and organizational measures to protect the information technology systems and Data in their possession, or otherwise in their administrative
control, and used in connection with the operation of the Company’s and its subsidiaries’ businesses, including reasonable efforts to establish and maintain, and having established, maintained, implemented and complied with, reasonable
information technology, information security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and
security plans that are designed to protect against and prevent breach of and unauthorized destruction, loss, and unauthorized distribution, use, access, disablement, misappropriation or modification of any such information technology system or Data
(“Breach”) and (ii) to the Company’s knowledge, there has been no such Breach, and the Company and its subsidiaries have not been notified in writing of and have no knowledge of any event or condition that would reasonably
be expected to result in, any such Breach. 
 (z) No material labor dispute with the employees of the Company or any of its
subsidiaries exists, except as described in the Time of Sale Memorandum and the Final Memorandum, or, to the knowledge of the Company, is imminent. 

(aa) The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for, other than as would not reasonably be
expected to have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, except as described in the Time of Sale Memorandum and the Final Memorandum. 

  
 10 

 (bb) The Company and its subsidiaries possess all certificates,
authorizations and permits issued by the appropriate U.S. federal, state, local or non-U.S. regulatory authorities necessary to conduct their respective businesses except such as the failure of which to obtain
would not reasonably be expected to have a Material Adverse Effect, and neither the Company nor, to the knowledge of the Company, any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except as described in the Time of Sale Memorandum and the Final
Memorandum. 
 (cc) The Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to
provide reasonable assurance that transactions are executed in accordance with management’s general or specific authorizations; transactions are recorded as necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles and to maintain asset accountability; access to assets is permitted only in accordance with management’s general or specific authorization; and the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. 
 (dd) Each periodic report
containing financial statements filed with the Commission by the Company since July 3, 2020 pursuant to Section 13(a) of the Exchange Act complied with the requirements of such section and the information in such reports fairly presented,
in all material respects, the financial condition and results of operations of the Company, as of the date of each such filing. 

(ee) Neither the Company, nor any affiliate (as defined in Rule 501(b) of Regulation D under the Securities Act, an
“Affiliate”) of the Company has directly, or through any person acting on its or their behalf, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act)
which is or will be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities, made any General Solicitation that is not an Additional Written Offering Communication
other than General Solicitations listed 

  
 11 

 
on Schedule II hereto or those made with the prior written consent of Morgan Stanley & Co. LLC, or offered, solicited offers to buy or sold the Securities in any manner involving a
public offering within the meaning of Section 4(a)(2) of the Securities Act (provided that no representation is made with respect to any Initial Purchaser). 

(ff) None of the Company, its Affiliates or any person acting on its or their behalf has engaged or will engage in any directed
selling efforts (within the meaning of Regulation S) with respect to the Securities and the Company, its Affiliates and any person acting on its or their behalf have complied and will comply with the offering restrictions requirement of Regulation S
(provided that no representation is made with respect to any Initial Purchaser). 
 (gg) Assuming the accuracy of the
representations and warranties of the Initial Purchasers contained in Section 7 hereof and their compliance with the agreements set forth therein, it is not necessary in connection with the offer, sale and delivery of the Securities to the
Initial Purchasers in the manner contemplated by this Agreement to register the Securities under the Securities Act or to qualify the Indentures under the Trust Indenture Act of 1939, as amended. 

(hh) The Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act. 

(ii) The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Preliminary
Memorandum, the Time of Sale Memorandum or the Final Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. 

2. Agreements to Sell and Purchase. The Issuer hereby agrees to sell to the several Initial Purchasers, and each Initial Purchaser, upon
the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Issuer the respective principal amount of Securities, as applicable, set
forth in Schedule I hereto opposite its name at a purchase price of (a) in the case of the 2029 Notes, 99.00% of the principal amount thereof (the “2029 Purchase Price”) and (b) in the case of the 2031 Notes, 99.00%
of the principal amount thereof (the “2031 Purchase Price,” and each of the 2029 Purchase Price and the 2031 Purchase Price, as applicable, the “Purchase Price”), in each case payable on the Closing Date (as defined
in Section 4 hereof). 

  
 12 

 3. Terms of Offering. You have advised the Issuer that the Initial Purchasers will
make an offering of the Securities purchased by the Initial Purchasers hereunder as soon as practicable after this Agreement is entered into as in your judgment is advisable. 

4. Payment and Delivery. Payment for the Securities shall be made to the Company in Federal or other funds immediately available in New
York City against delivery of such Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on December 8, 2020 or at such other time on the same or such other date, not more than five business
days after the foregoing date, as may be mutually agreed upon by the Issuer and you. The time and date of such payment are hereinafter referred to as the “Closing Date.” 

The Securities shall be in definitive form or global form, as specified by you, and registered in such names and in such denominations as you
shall request in writing not later than one full business day prior to the Closing Date. The Notes shall be delivered to you on the Closing Date for the respective accounts of the several Initial Purchasers, with any transfer taxes payable in
connection with the transfer of the Securities to the Initial Purchasers duly paid, against payment of the Purchase Price therefor plus accrued interest, if any, to the date of payment and delivery. 

5. Conditions to the Initial Purchasers’ Obligations. The several obligations of the Initial Purchasers to purchase
and pay for the Securities on the Closing Date are subject to the following conditions: 
 (a) Subsequent to the execution
and delivery of this Agreement and prior to the Closing Date: 
 (i) there shall not have occurred any downgrading, nor shall
any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the Company or any of its
subsidiaries or in the rating outlook for the Company by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act; and 

(ii) there shall not have occurred any change, or any development involving a prospective change, in the condition, financial
or otherwise, or in the earnings, business or operations of Company and its subsidiaries, taken as a whole, from that set forth in or contemplated by the Time of Sale Memorandum as of the date of this Agreement that, in the Initial Purchasers’
judgment, is material and adverse and that makes it, in the Initial Purchasers’ judgment, impracticable to proceed with the offering, sale and delivery of the Securities on the terms and in the manner contemplated in the Time of Sale
Memorandum. 

  
 13 

 (b) The Initial Purchasers shall have received on the Closing Date a
certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect set forth in Section 5(a)(i) and to the effect that, to such officer’s knowledge after due inquiry, the representations and warranties of
the Issuer and the Company contained in this Agreement that are qualified as to materiality or material adverse effect are true and correct, and those not so qualified are true and correct in all material respects, as of such date; and each of the
Issuer and the Company has complied in all material respects with all of the agreements and has satisfied in all material respects all of the conditions on its part to be performed or satisfied hereunder on or before such date. 

(c) The Initial Purchasers shall have received on the Closing Date an opinion of Wilson Sonsini Goodrich & Rosati,
P.C., outside U.S. counsel for the Issuer and the Company, dated the Closing Date, to the effect set forth in Exhibit B-1 and a disclosure letter of Wilson Sonsini Goodrich & Rosati, P.C., dated the
Closing Date, to the effect set forth in Exhibit B-2. Such opinion and letter shall be rendered to the Initial Purchasers at the request of the Issuer and the Company and shall so state therein. 

(d) The Initial Purchasers shall have received on the Closing Date an opinion of (x) Maples and Calder, outside Cayman
Islands counsel for the Issuer, dated the Closing Date, to the effect set forth in Exhibit C, (y) Arthur Cox, outside Irish counsel for the Company, dated the Closing Date, to the effect set forth in Exhibit D, and (z) Katherine E.
Schuelke, Senior Vice President, Chief Legal Officer and Company Secretary, dated the Closing Date to the effect set forth in Exhibit E. 

(e) The Initial Purchasers shall have received on the Closing Date an opinion of Davis Polk & Wardwell LLP, U.S.
counsel for the Initial Purchasers, dated the Closing Date, and a disclosure letter of Davis Polk & Wardwell LLP, dated the Closing Date, in form and substance satisfactory to the Initial Purchasers. 

(f) The Initial Purchasers shall have received on each of the date hereof and the Closing Date a letter, dated the date hereof
or the Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers, from Ernst & Young LLP, independent registered public accounting firm, containing statements and information of the type

  
 14 

 
ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in or incorporated by
reference into the Time of Sale Memorandum and the Final Memorandum; provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date that is three
business days prior to the Closing Date. 
 6. Covenants of the Issuer and the Company. The Issuer and the Company, jointly and
severally, covenant with each Initial Purchaser as follows: 
 (a) To furnish to you in New York City, without charge, prior
to 10:00 a.m. New York City time on the second business day next succeeding the date of this Agreement and during the period mentioned in Section 6(d) or (e), as many copies of the Time of Sale Memorandum, the Final Memorandum, any documents
incorporated by reference therein and any supplements and amendments thereto as you may reasonably request. 
 (b) Before
amending or supplementing the Time of Sale Memorandum or the Final Memorandum, to furnish to you a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which you reasonably object. 

(c) To furnish to you a copy of each proposed Additional Written Offering Communication (other than those identified on
Schedule II hereto) to be prepared by or on behalf of, used by, or referred to by the Issuer and the Company and not to use or refer to any such proposed Additional Written Offering Communication to which you reasonably object. 

(d) If the Time of Sale Memorandum is being used to solicit offers to buy the Securities at a time when the Final Memorandum is
not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Memorandum in order to make the statements therein, in the light of the
circumstances, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Time of Sale Memorandum to comply with applicable law, forthwith to prepare and furnish, at its own expense, to
the Initial Purchasers and to any dealer upon request, either amendments or supplements to the Time of Sale Memorandum so that the statements in the Time of Sale Memorandum as so amended or supplemented will not, in the light of the circumstances
when delivered to a prospective purchaser, be misleading or so that the Time of Sale Memorandum, as amended or supplemented, will comply with applicable law. 

  
 15 

 (e) If, during such period after the date hereof and prior to the date on
which all of the Securities shall have been sold by the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum in order to make the statements therein, in the
light of the circumstances when the Final Memorandum is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to comply with applicable law,
forthwith to prepare and furnish, at its own expense, to the Initial Purchasers, either amendments or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in the light of the
circumstances when the Final Memorandum is delivered to a purchaser, be misleading or so that the Final Memorandum, as amended or supplemented, will comply with applicable law. 

(f) To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as you
shall reasonably request provided, however, that nothing contained herein shall require the Company or any of its subsidiaries to qualify to do business in any jurisdiction, to execute a general consent to service of process in any state or
to subject itself to taxation in any jurisdiction in which it is otherwise not so subject. 
 (g) Whether or not the
transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under the Transaction Documents, including: the fees, disbursements
and expenses of counsel to the Issuer and the Company and accountants of the Issuer and the Company in connection with the issuance and sale of the Securities and all other fees or expenses in connection with the preparation of the Preliminary
Memorandum, the Time of Sale Memorandum, the Final Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Issuer and the Company and any amendments and supplements to any of the
foregoing, including all printing costs associated therewith, and the delivering of copies thereof to the Initial Purchasers, in the quantities herein above specified, all costs and expenses related to the transfer and delivery of the Securities to
the Initial Purchasers, including any transfer or other taxes payable thereon, the cost of printing or producing any Blue Sky or legal investment memorandum in connection with the offer and sale of the

  
 16 

 
Securities under state securities laws and all expenses in connection with the qualification of the Securities for offer and sale under state securities laws as provided in Section 6(f)
hereof, including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection with such qualification and in connection with the Blue Sky or legal investment memorandum, provided that such fees
and disbursements shall not exceed $5,000, any fees charged by rating agencies for the rating of the Securities, the costs and charges of the Trustee and any transfer agent, registrar or depositary, the cost of the preparation, issuance and delivery
of the Securities, the costs and expenses of the Issuer and the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities, including, without limitation,
expenses associated with the preparation or dissemination of any electronic road show, expenses associated with production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations
with the prior approval of the Issuer and the Company, the travel and lodging expenses of the representatives and officers of the Issuer and the Company and any such consultants, and the cost of any aircraft chartered in connection with the road
show, the document production charges and expenses associated with printing this Agreement and all other cost and expenses incident to the performance of the obligations of the Issuer and the Company hereunder for which provision is not otherwise
made in this Section. It is understood, however, that except as provided in this Section, Section 8, and the last paragraph of Section 10, the Initial Purchasers will pay all of their costs and expenses, including fees and disbursements of
their counsel, their expenses in connection with any road show (including travel and lodging), transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make. 

(h) Neither the Company nor any of its Affiliates will sell, offer for sale or solicit offers to buy or otherwise negotiate in
respect of any security (as defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the registration under the Securities Act of the Securities. 

(i) To furnish you with any proposed General Solicitation to be made by the Company or on its behalf before its use, and not to
make or use any proposed General Solicitation without your prior written consent. 

  
 17 

 (j) While any of the Securities remain “restricted securities”
within the meaning of the Securities Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under the Securities Act, unless the Company is then subject to Section 13 or 15(d) of
the Exchange Act. 
 (k) None of the Company or any of its Affiliates or any person acting on its or their behalf (other than
the Initial Purchasers, as to which no covenant is given) will engage in any directed selling efforts (as that term is defined in Regulation S) with respect to the Securities; and the Company and its Affiliates and each person acting on its or their
behalf (other than the Initial Purchasers, as to which no covenant is given) will comply with the offering restrictions requirement of Regulation S. 

(l) During the period of one year after the Closing Date, the Company will not, and will not permit any of its subsidiaries to,
and it will use its commercially reasonable efforts to not permit any of its other affiliates (as defined in Rule 144 under the Securities Act) to resell any of the Securities which constitute “restricted securities” under Rule 144 that
have been reacquired by any of them. 
 (m) Not to take any action prohibited by Regulation M under the Exchange Act in
connection with the distribution of the Securities contemplated hereby. 
 (n) The Company will deliver to each Initial
Purchaser (or its agent), on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers to the extent required, together with copies of identifying documentation,
and the Company undertakes to provide such additional supporting documentation as each Initial Purchaser may reasonably request in connection with the verification of the foregoing Certification. 

Each of the Issuer and the Company also agree that, without the prior written consent of Morgan Stanley & Co. LLC on behalf of the
Initial Purchasers, it will not, and the Company agrees that it will not permit any of its subsidiaries to, during the period beginning on the date hereof and continuing to and including the Closing Date, offer, sell, contract to sell or otherwise
dispose of any debt securities, or warrants to purchase debt securities, of the Issuer or the Company that are substantially similar to the Securities (other than the sale of the Securities under this Agreement). 

7. Offering of Securities; Restrictions on Transfer. (a) Each Initial Purchaser, severally and not jointly, represents and warrants
that such Initial Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not jointly, agrees

  
 18 

 
with the Issuer and the Company that it will not solicit offers for, or offer or sell, such Securities by any General Solicitation, other than a permitted communication listed on Schedule II
hereto, or those made with the prior written consent of the Issuer and the Company or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act, and it will sell such Securities only to, persons that
it reasonably believes to be in the case of offers inside the United States, QIBs and in the case of offers outside the United States, to persons other than U.S. persons (“foreign purchasers,” which term shall include dealers or
other professional fiduciaries in the United States acting on a discretionary basis for foreign beneficial owners (other than an estate or trust)) in reliance upon Regulation S under the Securities Act that, in each case, in purchasing such
Securities are deemed to have represented and agreed as provided in the Time of Sale Memorandum and the Final Memorandum under the caption “Transfer Restrictions.” 

(b) Each Initial Purchaser, severally and not jointly, represents, warrants, and agrees with respect to offers and sales outside the United
States that: 
 (i) such Initial Purchaser understands that no action has been or will be taken in any jurisdiction by the
Issuer and the Company that would permit a public offering of the Securities, or possession or distribution of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or any other offering or publicity material relating to the
Securities, in any country or jurisdiction where action for that purpose is required; 
 (ii) such Initial Purchaser will
comply with all applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers Securities or has in its possession or distributes the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or
any such other material, in all cases at its own expense; 
 (iii) the Securities have not been registered under the
Securities Act and may not be sold within the United States or to, or for the account or benefit of, U.S. persons except in accordance with Rule 144A or Regulation S under the Securities Act or pursuant to another exemption from the
registration requirements of the Securities Act; 

  
 19 

 (iv) such Initial Purchaser has offered the Securities and will offer and
sell the Securities as part of their distribution at any time and otherwise until 40 days after the later of the commencement of the offering and the Closing Date, only in accordance with Rule 903 of Regulation S or as otherwise permitted
in Section 7(a); accordingly, neither such Initial Purchaser, its Affiliates nor any persons acting on its or their behalf have engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the
Securities, and any such Initial Purchaser, its Affiliates and any such persons have complied and will comply with the offering restrictions requirement of Regulation S; 

(v) such Initial Purchaser, in relation to each Member State of the European Economic Area and the United Kingdom (each, a
“Relevant State”), has not offered, sold or otherwise made available and will not offer, sell or otherwise make available the Securities to any retail investor in the European Economic Area (“EEA”) or the United
Kingdom (the “UK”). For these purposes, (a) a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID
II”); or (ii) a customer within the meaning of Directive 2016/97/EU, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as
defined in the Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and in respect of the UK The Prospectus (Amendment etc.) (EU Exit) Regulations 2019; and (b) the expression “offer” includes the communication in
any form and by any means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe the notes. Consequently no key information document required by Regulation (EU)
No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the notes or otherwise making them available to retail investors in the EEA or in the UK has been prepared and therefore offering or selling the notes or
otherwise making them available to any retail investor in the EEA or in the UK may be unlawful under the PRIIPs Regulation. This offering memorandum has been prepared on the basis that any offer of notes in any Member State of the EEA or in the UK
will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of notes. This offering memorandum is not a prospectus for the purposes of the Prospectus Regulation. References to
Regulations or Directives include, in relation to the UK, those Regulations or Directives as they form part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 or have been implemented in UK domestic law, as appropriate. 

  
 20 

 (vi) such Initial Purchaser has represented and agreed (A) that it has
only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the United Kingdom Financial Services and
Markets Act 2000) received by it in connection with the issue or sale of the Securities in circumstances in which Section 21(1) of such Act is complied with or does not apply to the Company and (B) it has complied and will comply with all
applicable provisions of such Act with respect to anything done by it in relation to any Securities in, from or otherwise involving the UK; 

(vii) such Initial Purchaser understands that the Securities have not been and will not be registered under the Securities and
Exchange Law of Japan, and represents that it has not offered or sold, and agrees not to offer or sell, directly or indirectly, any Securities in Japan or for the account of any resident thereof except pursuant to any exemption from the registration
requirements of the Securities and Exchange Law of Japan and otherwise in compliance with applicable provisions of Japanese law; and 

(viii) such Initial Purchaser agrees that, at or prior to confirmation of sales of the Securities, it will have sent to each
distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases Securities from it during the restricted period a confirmation or notice to substantially the following effect: 

“The Securities covered hereby have not been registered under the U.S. Securities Act of 1933 (the “Securities
Act”) and may not be offered and sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or (ii) otherwise until 40 days after the later of the commencement of
the offering and the closing date, except in either case in accordance with Regulation S (or Rule 144A if available) under the Securities Act. Terms used above have the meaning given to them by Regulation S.” 

  
 21 

 Terms used and not otherwise defined in this Section 7(b) have the meanings given to them by
Regulation S. 
 (c) Each Initial Purchaser, severally and not jointly, agrees not to use any Additional Written Offering Communication
other than those approved by the Company in advance in writing or those that, if this offering of Securities were registered under the Securities Act, would not result in the Company being required to file with the Commission under Rule 433(d) such
Additional Written Offering Communication as a free writing prospectus prepared by or on behalf of such Initial Purchaser that otherwise would not be required to be so filed by the Company, but for the action of the Initial Purchaser. 

(d) Each Initial Purchaser has not and, severally and not jointly, agrees that it will not enter into any contractual arrangement with any
distributor (within the meaning of Regulation S) with respect to the distribution of Securities, provided, however, that nothing in this provision precludes the Initial Purchasers from entering into any such contractual arrangement
(i) between and among themselves, (ii) with their respective affiliates or (iii) with the prior written consent of the Company. 

In addition to the foregoing, each Initial Purchaser acknowledges and agrees that the Issuer and the Company and, for purposes of the opinions
to be delivered to the Initial Purchasers pursuant to Section 5 hereof, counsels for the Issuer, the Company and the Initial Purchasers may rely upon the accuracy of the representations and warranties of the Initial Purchasers and their
compliance with their agreements contained in this Section 7, and each Initial Purchaser hereby consents to such reliance. 
 8.
Indemnity and Contribution. (a) The Issuer and the Company agree to jointly and severally indemnify and hold harmless each Initial Purchaser, each person, if any, who controls any Initial Purchaser within the meaning of either
Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of any Initial Purchaser within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and
liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact
contained in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Issuer and the Company, any General Solicitation made by the Issuer

  
 22 

 
and the Company, or the Final Memorandum or any amendment or supplement thereto, or caused by any omission or alleged omission to state therein a material fact necessary to make the statements
therein in the light of the circumstances under which they were made not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon
information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use therein. 

(b) Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Issuer and the Company and
their respective directors, their respective officers and each person, if any, who controls the Issuer or the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the
foregoing indemnity from the Issuer and the Company to such Initial Purchaser, but only with reference to information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use in
the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Issuer and the Company in accordance with Section 6(c), any General Solicitation
set forth in Schedule II hereto, or the Final Memorandum or any amendment or supplement thereto. 
 (c) In case any proceeding (including any
governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person against
whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the
indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to
retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or the named
parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm (in addition to any local counsel) for all such 

  
 23 

 
indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Morgan Stanley & Co. LLC, in the case of
parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No
indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been
sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 

(d) To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, (i) shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect the relative benefits received by the Issuer and the Company on the one hand and the Initial Purchasers on the other hand
from the offering of the Securities or (ii) if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in
clause 8(d)(i) above but also the relative fault of the Issuer and the Company on the one hand and of the Initial Purchasers on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Issuer and the Company on the one hand and the Initial Purchasers on the other hand in connection with the offering of the Securities shall be
deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (before deducting expenses) received by the Company and the total discounts and commissions received by the Initial Purchasers bear to the
aggregate offering price of the Securities. The relative fault of the Issuer and the Company on the one hand and of the Initial Purchasers on the other hand shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Issuer and the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of
Securities they have purchased hereunder, and not joint. 

  
 24 

 (e) The Issuer and the Company and the Initial Purchasers agree that it would not be just or
equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take account of
the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Initial
Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which the Securities resold by it in the initial placement of such Securities were offered to investors exceeds the amount of any damages that
such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any indemnified party at law or in equity. 
 (f) The indemnity and contribution provisions contained in this
Section 8 and the representations, warranties and other statements of the Issuer and the Company contained in this Agreement shall remain operative and in full force and effect regardless of any termination of this Agreement, any investigation
made by or on behalf of any Initial Purchaser, any person controlling any Initial Purchaser or any affiliate of any Initial Purchaser or by or on behalf of the Issuer, the Company, their officers or directors or any person controlling the Issuer or
the Company, and acceptance of and payment for any of the Securities. 
 9. Termination. The Initial Purchasers may terminate this
Agreement by notice given by you to the Issuer, if after the execution and delivery of this Agreement and prior to the Closing Date trading generally shall have been suspended or materially limited on, or by, as the case may be, any of the New York
Stock Exchange, the NYSE MKT, the NASDAQ Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, trading of any securities of the Company shall have been suspended on any exchange or in
any over-the-counter market, a material disruption in securities settlement, payment or clearance services in the United

  
 25 

 
States shall have occurred, any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or there shall have occurred any outbreak or
escalation of hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in your judgment,
impracticable or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum or the Final Memorandum. 

10. Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and delivery hereof by the
parties hereto. 
 If, on the Closing Date, any one or more of the Initial Purchasers shall fail or refuse to purchase Securities that it or
they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities (for each series of Notes) which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase is not more than one-tenth of the aggregate principal amount of Securities (for each series of Notes) to be purchased on such date, the other Initial Purchasers shall be obligated severally in the proportions that the principal
amount of Securities set forth opposite their respective names in Schedule I bears to the aggregate principal amount of Securities set forth opposite the names of all such non-defaulting Initial
Purchasers, or in such other proportions as you may specify, to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on such date; provided that in no event shall the
principal amount of Securities that any Initial Purchaser has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of one-ninth of such principal
amount of Securities without the written consent of such Initial Purchaser. If, on the Closing Date any Initial Purchaser or Initial Purchasers shall fail or refuse to purchase Securities which it or they have agreed to purchase hereunder on such
date and the aggregate principal amount of Securities with respect to which such default occurs is more than one-tenth of the aggregate principal amount of Securities to be purchased on such date, and
arrangements satisfactory to you and the Company for the purchase of such Securities are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any
non-defaulting Initial Purchaser, the Issuer or the Company. In any such case either you or the Issuer shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order
that the required changes, if any, in the Final Memorandum or in any other documents or arrangements may be effected. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in respect of any default
of such Initial Purchaser under this Agreement. 

  
 26 

 If this Agreement shall be terminated by the Initial Purchasers, or any of them, because of
any failure or refusal on the part of the Issuer or the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Issuer or the Company shall be unable to perform its obligations under this
Agreement, the Issuer and the Company will reimburse the Initial Purchasers or such Initial Purchasers as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Initial Purchasers in connection with this Agreement or the offering contemplated hereunder. 

11. Entire Agreement. This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the
extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Issuer, the Company and the Initial Purchasers with respect to the preparation of the Preliminary Memorandum, the
Time of Sale Memorandum, the Final Memorandum, the conduct of the offering of the Securities, and the purchase and sale of the Securities. 

(a) The Issuer and the Company acknowledge that in connection with the offering of the Securities: the Initial Purchasers have acted at arms
length, are not agents of, and owe no fiduciary duties to, the Issuer, the Company or any other person, the Initial Purchasers owe the Issuer and the Company only those duties and obligations set forth in this Agreement and prior written agreements
(to the extent not superseded by this Agreement) if any, and the Initial Purchasers may have interests that differ from those of the Issuer and the Company. The Issuer and the Company waives to the full extent permitted by applicable law any claims
it may have against the Initial Purchasers arising from an alleged breach of fiduciary duty in connection with the offering of the Securities. 

12. Counterparts. This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument. Delivery of a signature page hereto by facsimile transmission, electronic signature, or by other electronic transmission (including a “.pdf” or “.tif” file)
shall be as effective as delivery of a manually executed counterpart hereof. 
 13. Successors. This Agreement will inure to the
benefit of and be binding upon the parties hereto, and to the benefit of the indemnified parties referred to in Section 8 hereof, and in each case their respective successors, and no other person will have any right or obligation hereunder. The
term “successors” shall not include any subsequent purchaser or other purchaser of the Securities as such from any of the Initial Purchasers merely by reason of such purchase. 

  
 27 

 14. Applicable Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York. 
 15. Consent to Jurisdiction; Appointment of Agent for Service of Process. The
Issuer and the Company, jointly and severally, agree that: 
 (a) Any suit, action or proceeding against the Issuer or Company arising out of
or relating to this Agreement may be instituted in any state or U.S. Federal court in the Borough of Manhattan, The City of New York, New York, and any appellate court from any thereof, and the Issuer and the Company each irrevocably submit to the non-exclusive jurisdiction of such courts in any suit, action or proceeding. The Issuer and the Company each irrevocably waive, to the fullest extent permitted by law, any objection to any suit, action or proceeding
that may be brought in connection with this Agreement, including such actions, suits or proceedings relating to securities laws of the United States of America or any state thereof, in such courts whether on the grounds of venue, residence or
domicile or on the ground that any such suit, action or proceeding has been brought in an inconvenient forum. The final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Issuer or the
Company and may be enforced in any court to the jurisdiction of which the Issuer or the Company is subject by a suit upon such judgment; provided that service of process is effected upon the Issuer or the Company in the manner provided by
this Section 15. 
 (b) The Issuer and the Company each hereby appoint Seagate Technology (US) Holdings, Inc., as its authorized agent
(the “Authorized Agent”), upon whom process may be served in any suit, action or proceeding arising out of or relating to this Agreement or the transactions contemplated herein which may be instituted in any state or U.S. Federal
court in the Borough of Manhattan, The City of New York, New York, and expressly accepts the non-exclusive jurisdiction of any such court in respect of any such suit, action or proceeding. The Authorized Agent
hereby accepts such appointment and agrees to act as said agent for service of process. Service of process upon the Authorized Agent shall be deemed, in every respect, effective service of process upon the Issuer and the Company. Notwithstanding the
foregoing, any action involving the Issuer or the Company arising out of or relating to this Agreement may be instituted in any court of competent jurisdiction in any other jurisdiction. 

  
 28 

 (c) Any action, suit or proceeding brought by the Issuer and/or the Company against the
Initial Purchasers arising out of or based upon this Agreement and the transactions contemplated herein shall be brought solely in a U.S. Federal or state court in the Borough of Manhattan, The City of New York, New York, and the Issuer and the
Company shall not initiate or seek to initiate, in any other jurisdiction other than in such New York courts, any action, suit or proceeding against the Initial Purchasers arising out of or based upon this Agreement and the transactions contemplated
herein. The foregoing shall apply, without limitation, to any action seeking to obtain any injunction or declaratory judgment against the enforcement of, or a declaratory judgment concerning, any claim by the Initial Purchasers in respect of this
Agreement and any transaction contemplated herein, and any action challenging the enforceability of or seeking to invalidate in any respect the submission by the Issuer and the Company hereunder to the jurisdiction of such New York courts or the
designation, pursuant to this Section 15, of the laws of the State of New York as the law applicable to this Agreement. 
 (d) The
provisions of this Section 15 shall survive any termination or cancellation of this Agreement. 
 16. Judgment Currency. If for
the purposes of obtaining judgment in any court it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall
be the rate at which in accordance with normal banking procedures the Initial Purchasers could purchase United States dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given. The
obligation of the Issuer and the Company with respect to any sum due from it to any Initial Purchaser or any person controlling any Initial Purchaser shall, notwithstanding any judgment in a currency other than United States dollars, not be
discharged until the first business day following receipt by such Initial Purchaser or controlling person of any sum in such other currency, and only to the extent that such Initial Purchaser or controlling person may in accordance with normal
banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Initial Purchaser or controlling person hereunder, the Issuer and the Company, jointly
and severally, agree as a separate obligation and notwithstanding any such judgment, to indemnify such Initial Purchaser or controlling person against such loss. If the United States dollars so purchased are greater than the sum originally due to
such Initial Purchaser or controlling person hereunder, such Initial Purchaser or controlling person agrees to pay to the Issuer and Company an amount equal to the excess of the dollars so purchased over the sum originally due to such Initial
Purchaser or controlling person hereunder. 
 17. Headings. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement. 

  
 29 

 18. Notices. All communications hereunder shall be in writing and effective only upon
receipt and if to the Initial Purchasers shall be delivered, mailed or sent to Morgan Stanley & Co., LLC at 1585 Broadway, Floor 29, New York, New York 10036, Attention: Investment Banking Division (facsimile: (212) 507-8999), with a copy to the Legal Department; if to the Issuer, the Company or the Authorized Agent shall be delivered, mailed or sent to it at 47488 Kato Road, Fremont, California 94538, Attention: Katherine E.
Schuelke, Senior Vice President, Chief Legal Officer and Company Secretary. 
 19. Recognition of the U.S. Special Resolution Regimes.
(a) In the event that any Initial Purchaser that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Initial Purchaser of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of
the United States. 
 (b) In the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser
becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be
exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. 

For purposes of this Section a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall
be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R.
§ 382.2(b). “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable. “U.S. Special Resolution Regime”
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. 

  
 30 

 
					
	 SEAGATE HDD CAYMAN, 
 as
Issuer

		
	By:	 	 /s/ Walter Chang

		 	Name:	 	Walter Chang
		 	Title:	 	Treasurer
	
	 SEAGATE TECHNOLOGY PLC, 
 as
Guarantor

		
	By:	 	 /s/ Gianluca Romano

		 	Name:	 	Gianluca Romano
		 	Title:	 	Executive Vice President and Chief Financial Officer

 [Purchase Agreement Signature Page] 

 
			
	 Accepted as of the date hereof
  

MORGAN STANLEY & CO. LLC 
  

Acting severally on behalf of itself and the several Initial Purchasers named in Schedule I hereto.

 
 By: Morgan Stanley & Co. LLC

		
	By:	 	 /s/ Brian Sanderson

		 	Name: Brian Sanderson
		 	Title:   Authorized Signatory

 [Purchase Agreement Signature Page] 

 SCHEDULE I 

 

									
	 Initial Purchasers
	  	Principal Amount
of 2029 Notes to be
Purchased	 	  	Principal Amount
of 2031 Notes to be
Purchased	 
	 Morgan Stanley & Co. LLC
	  	$	125,000,000	 	  	$	125,000,000	 
	 BofA Securities, Inc.
	  	 	60,000,000	 	  	 	60,000,000	 
	 MUFG Securities Americas Inc.
	  	 	60,000,000	 	  	 	60,000,000	 
	 Scotia Capital (USA) Inc.
	  	 	60,000,000	 	  	 	60,000,000	 
	 Wells Fargo Securities, LLC
	  	 	50,000,000	 	  	 	50,000,000	 
	 KKR Capital Markets LLC
	  	 	40,000,000	 	  	 	40,000,000	 
	 BNP Paribas Securities Corp.
	  	 	35,000,000	 	  	 	35,000,000	 
	 DBS Bank Ltd.
	  	 	10,000,000	 	  	 	10,000,000	 
	 ICBC Standard Bank Plc
	  	 	10,000,000	 	  	 	10,000,000	 
	 Mizuho Securities USA LLC
	  	 	10,000,000	 	  	 	10,000,000	 
	 Oversea-Chinese Banking Corporation Limited
	  	 	10,000,000	 	  	 	10,000,000	 
	 Samuel A. Ramirez & Company, Inc.
	  	 	10,000,000	 	  	 	10,000,000	 
	 SMBC Nikko Securities America, Inc.
	  	 	10,000,000	 	  	 	10,000,000	 
	 U.S. Bancorp Investments, Inc.
	  	 	10,000,000	 	  	 	10,000,000	 
		  	  
	  
	 	  	  
	  
	 
	 Total:
	  	$	500,000,000	 	  	$	500,000,000	 
		  	  
	  
	 	  	  
	  
	 

  
 I-1 

 SCHEDULE II 

Permitted Communications 
 Permitted
Additional Written Offering Communications 
 1. Pricing Term Sheet dated December 3, 2020, attached as Exhibit A hereto 

Permitted General Solicitations other than Permitted Additional Written Offering Communications set forth above 

None. 

  
 II-1 

 EXHIBIT A 

PRICING TERM SHEET 

Seagate HDD Cayman 

Pricing Term Sheet 

December 3, 2020 

3.125% Senior Notes due 2029 

3.375% Senior Notes due 2031 
 This
Pricing Term Sheet dated December 3, 2020 (this “Pricing Term Sheet”) supplements the Preliminary Offering Memorandum dated December 2, 2020 of Seagate HDD Cayman (the “Preliminary Offering Memorandum”) and supersedes
the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Preliminary
Offering Memorandum. 
  

			
		
	Issuer:	  	Seagate HDD Cayman
		
	Guarantor:	  	Seagate Technology plc, a public limited company organized under the laws of Ireland
		
	Gross Proceeds:	  	$1,000,000,000
		
	Trade Date:	  	December 3, 2020
		
	Settlement Date*:	  	December 8, 2020 (T+3)
		
	Ratings (Moody’s / S&P / Fitch)**:	  	Ba1/BB+/BB+
		
	Joint Lead and Joint Bookrunning	  	
	Managers:	  	Morgan Stanley & Co. LLC
		  	BofA Securities, Inc.
		  	MUFG Securities Americas Inc.
		  	Scotia Capital (USA) Inc.
		  	Wells Fargo Securities, LLC
		  	KKR Capital Markets LLC
		  	BNP Paribas Securities Corp.
		
	Co-Managers:	  	DBS Bank Ltd.
		  	ICBC Standard Bank Plc
		  	Mizuho Securities USA LLC
		  	Oversea-Chinese Banking Corporation Limited
		  	Samuel A. Ramirez & Company, Inc.
		  	SMBC Nikko Securities America, Inc.
		  	U.S. Bancorp Investments, Inc.
		
	Distribution:	  	Rule 144A/Regulation S (with registration rights)
	
	Terms Relating to the 3.125% Senior Notes due 2029
		
	Security Description:	  	3.125% Senior Notes due 2029 (the “2029 Notes”)
		
	Principal Amount:	  	$500,000,000
		
	Coupon:	  	3.125%
		
	Maturity:	  	July 15, 2029
		
	Offering Price:	  	100.0%, plus accrued interest, if any, from December 8, 2020
		
	Yield to Maturity:	  	3.125%
		
	Spread to Treasury:	  	+232 basis points
		
	Benchmark:	  	2.375% UST due May 15, 2029

					
	Benchmark Treasury Yield:	  	0.810%
		
	Interest Payment Dates:	  	January 15 and July 15, beginning on July 15, 2021
		
	Optional Redemption:	  	At any time prior to January 15, 2024, the Issuer may redeem some or all of the 2029 Notes at a price of 100% of the principal amount of such notes redeemed plus the “make-whole premium” (as defined
below), plus accrued and unpaid interest, if any, to, but excluding the redemption date. “Make-whole premium” means, with respect to any 2029 Note on any redemption date, the greater of (1) 1.0% of the principal amount of such note and
(2) the excess, if any, of (a) the present value at such redemption date of (i) the applicable redemption price of such note that would apply if such notes were redeemed on January 15, 2024 (such redemption price (expressed in
percentage of principal amount) being set forth in the table appearing below), plus (ii) all remaining scheduled payments of interest due on such notes to and including January 15, 2024, computed using a discount rate equal to the Treasury
Rate as of such redemption date plus 50 basis points; over (b) the sum of accrued and unpaid interest, if any, to but excluding the redemption date, plus the principal amount of such notes.
		
		  	At any time on or after January 15, 2024, the Issuer may redeem some or all of such 2029 Notes at the redemption prices (expressed in percentage of principal amount) set forth below, plus accrued and unpaid interest
to, but excluding, the redemption date.
			
		  	Period Beginning January 15, 	  	Price
			
		  	2024	  	101.563%
			
		  	2025	  	100.781%
			
		  	2026 and thereafter	  	100.000%
		
	Equity Clawback:	  	At any time prior to January 15, 2024, the Issuer may redeem up to 40% of the principal amount of outstanding for the 2029 Notes (including additional 2029 Notes, if any) with the net cash proceeds of one or more
equity offerings at a redemption price (expressed as a percentage of principal amount) of 103.125%, plus accrued interest to, but excluding, the redemption date; provided that (i) at least 60% of the aggregate principal amount of the
2029 Notes originally issued on the date of the 2029 Notes indenture remains outstanding after such redemption, and (ii) notice of any such redemption is mailed within 60 days of the closing of the related equity offering.
		
	Change of Control:	  	101% of the principal amount of the 2029 Notes plus accrued and unpaid interest, if any, to the date of repurchase
		
	CUSIP Numbers:	  	144A/Reg S:             81180W BA8 / G79456 AN2
		
	ISIN Numbers:	  	144A/Reg S:             US81180WBA80 / USG79456AN24
		
	Denominations:	  	$2,000
		
	Increments:	  	$1,000
	
	Terms Relating to the 3.375% Senior Notes due 2031
		
	Security Description:	  	3.375% Senior Notes due 2031 (the “2031 Notes”)
		
	Principal Amount:	  	$500,000,000
		
	Coupon:	  	3.375%
		
	Maturity:	  	July 15, 2031

					
	Offering Price:	  	100.0%, plus accrued interest, if any, from December 8, 2020
		
	Yield to Maturity:	  	3.375%
		
	Spread to Treasury:	  	+251 basis points
		
	Benchmark:	  	5.375% UST due February 15, 2031
		
	Benchmark Treasury Yield:	  	0.862%
		
	Interest Payment Dates:	  	January 15 and July 15, beginning on July 15, 2021
		
	Optional Redemption:	  	At any time prior to January 15, 2026, the Issuer may redeem some or all of the 2031 Notes at a price of 100% of the principal amount of such notes redeemed plus the ““make-whole premium” (as defined
below), plus accrued and unpaid interest, if any, to, but excluding the redemption date. “Make-whole premium” means, with respect to any 2031 Note on any redemption date, the greater of (1) 1.0% of the principal amount of such note and
(2) the excess, if any, of (a) the present value at such redemption date of (i) the applicable redemption price of such note that would apply if such notes were redeemed on January 15, 2026 (such redemption price (expressed in
percentage of principal amount) being set forth in the table appearing below), plus (ii) all remaining scheduled payments of interest due on such notes to and including January 15, 2026, computed using a discount rate equal to the Treasury
Rate as of such redemption date plus 50 basis points; over (b) the sum of accrued and unpaid interest, if any, to but excluding the redemption date, plus the principal amount of such notes.
		
		  	At any time on or after January 15, 2026, the Issuer may redeem some or all of such 2031 Notes at the redemption prices (expressed in percentage of principal amount) set forth below, plus accrued and unpaid interest
to, but excluding, the redemption date.
			
		  	Period Beginning January 15, 	  	Price
			
		  	2026	  	101.688%
			
		  	2027	  	101.125%
			
		  	2028	  	100.563%
			
		  	2029 and thereafter	  	100.000%
		
	Equity Clawback:	  	At any time prior to January 15, 2024, the Issuer may redeem up to 40% of the principal amount of outstanding for the 2031 Notes (including additional 2031 Notes, if any) with the net cash proceeds of one or more
equity offerings at a redemption price (expressed as a percentage of principal amount) of 103.375%, plus accrued interest to, but excluding, the redemption date; provided that (i) at least 60% of the aggregate principal amount of the
2031 Notes originally issued on the date of the 2031 Notes indenture remains outstanding after such redemption, and (ii) notice of any such redemption is mailed within 60 days of the closing of the related equity offering.
		
	Change of Control:	  	101% of the principal amount of the 2031 Notes, plus accrued and unpaid interest, if any, to the date of repurchase
		
	CUSIP Numbers:	  	144A/Reg S:             81180W BB6 / G79456 AP7
		
	ISIN Numbers:	  	144A/Reg S:             US81180WBB63 / USG79456AP71
			
	Denominations:	  	$2,000	  	
			
	Increments:	  	$1,000	  	

	*	 Delivery of the 2029 Notes and 2031 Notes (the “Notes”) is expected on or about December 8,
2020 which will be the third business day following the date of pricing of the Notes (such settlement cycle being referred to as “T+3”). Under Rule 15c6-1 of the U.S. Securities Exchange Act of 1934,
as amended, trades in the secondary market generally are required to settle in two business days unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers that wish to trade the Notes more than two business days prior
to the delivery of the Notes will be required, by virtue of the fact that the Notes initially will settle in T+3, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the Notes that
wish to trade the Notes prior to their date of delivery hereunder should consult their own advisor. 

	**	 Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time. 

 The Notes have not been registered under the U.S. Securities Act of 1933, as amended (the
“Securities Act”), or the laws of any other place, and are being offered only (1) to “qualified institutional buyers” as defined in Rule 144A under the Securities Act and (2) outside the United States in compliance with
Regulation S under the Securities Act. 
 Any disclaimers or other notices that may appear below are not applicable to this communication and should
be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg email or another communication system. 

 EXHIBIT B-1 

FORM OF OPINION OF WILSON SONSINI GOODRICH & ROSATI, P.C. 
  

	1.	 The Purchase Agreement has been duly executed and delivered by each of the Issuer and the Guarantor in
accordance with the law of the State of New York. 

  

	2.	 Each Indenture has been duly executed and delivered by each of the Issuer and the Guarantor in accordance with
the law of the State of New York, and each Indenture constitutes a valid and binding obligation, enforceable against each of the Issuer and the Guarantor in accordance with its terms. 

 

	3.	 The Notes have been duly executed by the Issuer in accordance with the law of the State of New York and when
authenticated by the Trustee in accordance with the terms of the applicable Indenture and issued and delivered to the Initial Purchasers against payment of the purchase price therefor specified in the Purchase Agreement, the Notes and the Guarantees
will constitute valid and binding obligations of the Issuer and the Guarantor, respectively, enforceable against each of the Issuer and the Guarantor, respectively, in accordance with their terms; and are entitled to the benefits of the applicable
Indenture. 

  

	4.	 The Registration Rights Agreements have been duly executed and delivered by the Issuer and the Guarantor in
accordance with the law of the State of New York and each constitutes a valid and binding obligation, enforceable against each of the Issuer and the Guarantor in accordance with its terms. 

 

	5.	 The execution and delivery by the Issuer and the Guarantor of the Operative Documents to which each is a party,
the performance by the Issuer and the Guarantor of their respective obligations under the Purchase Agreement and the undertaking of the covenants set forth in the Operative Documents to which each is a party, and the issuance and sale of the
Securities or the consummation of any other of the transactions contemplated thereby do not violate or, with respect to clause (B) of this paragraph, constitute a default under, (A) any provision of any federal or New York state law, rule
or regulation known to us to be customarily applicable to transactions of the nature contemplated by the Purchase Agreement; or (B) any Reviewed Agreement. 

 

	6.	 No consent, approval, authorization of, or designation, declaration or filing with, any governmental authority
on the part of the Issuer or the Guarantor is required for the valid execution and delivery of the Purchase Agreement or the consummation of the transactions contemplated thereby or by the Indentures or the Registration Rights Agreements, or the
offer, sale or issuance of the Securities, except as may be expressly contemplated by the Purchase Agreement, the Indentures, the Registration Rights Agreements or the Securities and such consents, approvals, authorizations, designations,
declarations or filings as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Securities by the Initial Purchasers. 

	7.	 The statements set forth in the Disclosure Package and the Final Offering Memorandum under the caption
“Description of Notes”, insofar as such statements purport to constitute a summary of the terms of the Indentures and the Securities, fairly and accurately summarize the matters referred to therein in all material respects.

  

	8.	 The statements set forth in the Disclosure Package and the Final Offering Memorandum under the caption
“United States Federal Income Tax Considerations”, insofar as such statements purport to constitute a summary of the United States federal tax laws referred to therein or legal conclusions with respect thereto, fairly and accurately
summarize the matters referred to therein in all material respects. 

  

	9.	 The Issuer and the Guarantor are not and, immediately after giving effect to the offering and sale of the Notes
to be sold by the Issuer and the application of the proceeds thereof as described in the Disclosure Package and the Final Offering Memorandum, will not be required to register as an “investment company” as such term is defined in the
Investment Company Act of 1940. 

  

	10.	 No registration of the Securities under the Act and no qualification of an indenture under the Trust Indenture
Act with respect thereto, is required for the offer, sale and delivery of the Securities by the Issuer and the Guarantor to the Initial Purchasers pursuant to the Purchase Agreement and the initial resale of the Securities by the Initial Purchasers
in the manner contemplated by the Purchase Agreement and the Final Offering Memorandum (it being understood that no opinion is expressed as to any subsequent resale of the Securities). 

 EXHIBIT B-2 

FORM OF DISCLOSURE LETTER OF 

WILSON SONSINI GOODRICH & ROSATI, P.C. 

In the course of such participation, review and discussion no facts have come to our attention that have caused us to believe that: 

(i) the Pricing Disclosure Package, as of 3:25 p.m. New York time on December 3, 2020, contained an untrue statement of a
material fact or omitted to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, or 

(ii) the Final Offering Memorandum, as of its issue date or as of the date hereof, contained or contains an untrue statement of
a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

 EXHIBIT C 

FORM OF OPINION OF MAPLES AND CALDER 
  

	1	 Opinions 

Based upon, and subject to, the foregoing assumptions and the qualifications set out below, and having regard to such legal considerations as we deem
relevant, we are of the opinion that: 
  

	1.1	 The Issuer has been duly incorporated as an exempted company with limited liability and is validly existing and
in good standing with the Registrar of Companies under the laws of the Cayman Islands. 

  

	1.2	 The Issuer has all requisite power and authority under the Memorandum and Articles of Association to enter
into, execute and perform its obligations under the Transaction Documents and the Notes. 

  

	1.3	 The execution and delivery of the Transaction Documents do not, and the issue and offer of the Notes by the
Company and the performance by the Issuer of its obligations thereunder will not, conflict with or result in a breach of any of the terms or provisions of the Memorandum and Articles, or any law, public rule or regulation applicable to the Issuer
currently in force in the Cayman Islands. 

  

	1.4	 The execution, delivery and performance of the Transaction Documents have been authorised by and on behalf of
the Issuer and, assuming the Transaction Documents have been executed and unconditionally delivered by a duly authorised signatory of the Issuer the Transaction Documents, have been duly executed and delivered on behalf of the Issuer, and constitute
the legal, valid and binding obligations of the Issuer enforceable in accordance with their terms. 

  

	1.5	 The Notes have been duly authorised by the Issuer and when the Notes are signed in facsimile or manually by an
authorised signatory of the Issuer and, when, authenticated in the manner set forth in the Indentures and delivered against due payment, the conditions relating to the issuance of the Notes contained in the Indentures have been satisfied and when
appropriate entries are made in the securities register in respect of the Notes, the Notes will be duly executed, issued and delivered and the Notes will constitute the legal, valid and binding obligations of the Issuer enforceable in accordance
with their respective terms. 

  

	1.6	 No authorisations, consents, approvals, licences, validations or exemptions are required by law from any
governmental authorities or agencies or other official bodies in the Cayman Islands in connection with: 

  

	 	(a)	 the creation, execution or delivery of the Transaction Documents and the Notes by the Issuer;

  
 C-8 

	 	(b)	 subject to the payment of the appropriate stamp duty, enforcement of the Transaction Documents and the Notes
against the Issuer; or 

  

	 	(c)	 the performance by the Issuer of its obligations under any of the Transaction Documents, and the Notes.

  

	1.7	 Except as set forth in the qualification at paragraph 4.3 below, no stamp duties, taxes, fees or charges are
payable (either by direct assessment or withholding) to the government or other taxing authority in the Cayman Islands under the laws of the Cayman Islands in respect of: 

 

	 	(a)	 the creation, offering, issue or delivery of the Notes; 

 

	 	(b)	 the execution or delivery of the Transaction Documents and the Notes; 

 

	 	(c)	 the enforcement or admissibility in evidence of the Transaction Documents and the Notes; 

 

	 	(d)	 payments made under, or pursuant to, the Transaction Documents and the Notes; or 

 

	 	(e)	 gains derived from the disposal of the Notes. 

The Cayman Islands currently have no form of income, corporate or capital gains tax and no estate duty, inheritance tax or gift tax. 

 

	1.8	 The courts of the Cayman Islands will observe and give effect to the choice of the Relevant Law as the
governing law of the Transaction Documents and the Notes. 

  

	1.9	 Based solely on our search of the Register of Writs and Other Originating Process (together, the “Court
Register”) maintained by the Clerk of the Court of the Grand Court of the Cayman Islands from the date of incorporation of the Issuer to the close of business (Cayman Islands time) on [•] December 2020 (the “Litigation
Search”), the Court Register disclosed no writ, originating summons, originating motion, petition (including any winding up petition), counterclaim nor third party notice (“Originating Process”) nor any amended Originating
Process pending before the Grand Court of the Cayman Islands, in which the Issuer is identified as a defendant or respondent. 

  

	1.10	 Although there is no statutory enforcement in the Cayman Islands of judgments obtained in the Relevant
Jurisdiction, a judgment obtained in such jurisdiction will be recognised and enforced in the courts of the Cayman Islands at common law, without any re-examination of the merits of the underlying dispute, by
an action commenced on the foreign judgment debt in the Grand Court of the Cayman Islands, provided such judgment: 

  

	 	(a)	 is given by a foreign court of competent jurisdiction; 

  
 C-9 

	 	(b)	 imposes on the judgment debtor a liability to pay a liquidated sum for which the judgment has been given;

  

	 	(c)	 is final; 

  

	 	(d)	 is not in respect of taxes, a fine or a penalty; and 

 

	 	(e)	 was not obtained in a manner and is not of a kind the enforcement of which is contrary to natural justice or
the public policy of the Cayman Islands. 

  

	1.11	 It is not necessary to ensure the legality, validity, enforceability or admissibility in evidence of the
Transaction Documents or the Notes that any document be filed, recorded or enrolled with any governmental authority or agency or any official body in the Cayman Islands. 

 

	1.12	 The Issuer is free to acquire, sell and hold foreign currencies and to issue securities and obligations
denominated in a foreign currency under the laws of the Cayman Islands. The Cayman Islands currently have no foreign exchange control laws or regulations. 

  

	1.13	 None of the parties to the Transaction Documents (other than the Issuer) or the holders of Notes is or will be
treated as resident, domiciled or carrying on or transacting business in the Cayman Islands solely by reason of the negotiation, preparation or execution of the Transaction Documents and the Notes. 

 

	1.14	 The submission by the Issuer under the Transaction Documents and the Notes to the non-exclusive jurisdiction of the Relevant Jurisdiction is legal, valid and binding on the Issuer assuming that the same is true under the governing law of the Transaction Documents and the Notes and under the laws,
rules and procedures applying in Relevant Jurisdiction. 

  

	1.15	 The Issuer is not entitled to any immunity under the laws of the Cayman Islands whether characterised as
sovereign immunity or otherwise for any legal proceedings in the Cayman Islands to enforce or to collect upon the Transaction Documents or the Notes (including, without limitation, immunity from service of process, immunity from jurisdiction prior
to entry of judgment or from attachment in aid of execution upon a judgment in respect of itself or its property). 

  

	1.16	 None of the parties to the Transaction Documents (other than the Issuer) is required to be licensed, qualified
or otherwise entitled to carry on business in the Cayman Islands in order to enforce its rights under, or by reason of the execution or delivery and performance (outside of the Cayman Islands) of, any of the Transaction Documents to which it is a
party. 

  

	1.17	 There is no applicable money or interest limitation law in the Cayman Islands which may restrict the recovery
of any amount expressed to be payable under or in connection with the Notes. 

  
 C-10 

 EXHIBIT D 

FORM OF OPINION OF ARTHUR COX 
  

	1.	 Opinion 

Subject to the assumptions and qualifications set out in this Opinion, we are of the opinion that: 

Capacity, Authority and Status 
  

	 	1.1	 The Company is a public limited company and is duly incorporated and validly existing under the laws of
Ireland. 

  

	 	1.2	 The Company has the necessary corporate power and authority under its Constitution to execute and deliver any
and all of the Transaction Documents and to perform its obligations thereunder in accordance with the terms thereof. 

  

	 	1.3	 The entry into the Transaction Documents by the Company and the performance of its obligations thereunder does
not contravene: 

  

	 	(a)	 any law of Ireland applicable to the Company; or 

 

	 	(b)	 the Company’s Constitution. 

 

	 	1.4	 All necessary corporate action required on the part of the Company to authorise the execution and delivery of
the Transaction Documents and the performance by the Company of its obligations thereunder has been duly taken and the Transaction Documents have been duly executed by the Company. 

 

	 	1.5	 No consent, authorisation, licence or approval or other action from any Irish governmental or public body or
public authority and no registration, filing or recording of any of the Transaction Documents or any instrument relating thereto in any Irish public office, governmental authority or regulatory body is necessary under the laws of Ireland to ensure
the validity and enforceability of the Transaction Documents against the Company or is required in connection with the execution and delivery of the Transaction Documents and performance by the Company of the Transaction Documents.

  
 D-1 

	 	1.6	 The Company does not have any immunity from the jurisdiction of any court or from any legal process (whether
through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) under the laws of Ireland. 

  

	 	1.7	 Based only on the Corporate Certificate and the Searches, the Company has not taken any corporate action for
its winding up, dissolution, court protection or reorganisation or for the appointment of an examiner, liquidator, trustee or similar officer in respect of the Company or any or all of its assets. No other party has taken any action or commenced any
proceedings for the winding up, dissolution, court protection or reorganisation of the Company or for the appointment of a receiver, liquidator, examiner, trustee or similar officer in respect of the Company or any or all of the Company’s
assets, revenues or undertakings. 

 No Licences required 

 

	 	1.8	 It is not necessary that the Trustee or any of the Initial Purchasers be licensed, qualified or otherwise
entitled to carry on business in Ireland to enable them to execute the Transaction Documents to which they are a party and perform their obligations under the Transaction Documents to which they are a party. 

Taxes 
  

	 	1.9	 The Company should not be required to make any deduction or withholding for or on account of Irish income tax
from payments pursuant to the Notes Guarantees. 

  

	 	1.10	 Under the laws of Ireland there is no stamp duty or similar charges or duties payable in Ireland in relation to
the Transaction Documents. 

  

	 	1.11	 The statements in the Time of Sale Memorandum and the Final Memorandum entitled “Ireland Tax
Considerations” are correct as to legal matters in all material aspects in so far as they summarise the laws of Ireland relating to tax. 

  

	 	1.12	 Neither the Trustee nor any of the Initial Purchasers is or will be deemed to be resident, domiciled or
carrying on business in Ireland solely by reason of entering into the Transaction Documents. 

  
 D-2 

 Interest 
  

	 	1.13	 There is no interest limitation law in Ireland which would apply to the Company and which would restrict the
recovery of any amount expressed to be payable under or in connection with the Notes or the Notes Guarantees by the Company. 

Governing law and jurisdiction 
  

	 	1.14	 In any proceedings taken in Ireland for the enforcement of the Transaction Documents, the choice of the laws of
the State of New York as the governing law of any of the Transaction Documents will be recognised by the courts of Ireland pursuant to Article 3 of the Rome I Regulation (EC) No. 593/2008 of the European Parliament and of the Council of
17 June 2008 on the law applicable to contractual obligations (the “Rome I Regulation”) with respect to matters falling within the scope of the Rome I Regulation. 

 

	 	1.15	 Council Regulation (EC) No 864/2007 of 11 July 2007 on the law applicable to non-contractual obligations (the “Rome II Regulation”) has force of law in Ireland. The incorporation of the laws of the State of New York as the governing law of
non-contractual obligations arising out of the Transaction Documents is, in each case, in respect of non-contractual obligations which are within the scope of the Rome
II Regulation, valid in accordance with Article 14(1) of the Rome II Regulation and, accordingly, the laws of the State of New York will be applied by the courts of Ireland if any claim to enforce such
non-contractual obligations against the Company comes under their jurisdiction. 

  

	 	1.16	 The courts of Ireland will enforce the submission by the Company to the jurisdiction of any State or U.S.
Federal Court in the Borough of Manhattan, The City of New York, New York to the extent so submitted and a judgment of any such court will be enforced by the courts of Ireland if the following general requirements are met: 

 

	 	(a)	 the foreign judgment is for a definite sum; 

 

	 	(b)	 the foreign court must have had jurisdiction in relation to the particular defendant according to Irish
conflict of law rules (the submission to jurisdiction by the defendant would satisfy this rule); and 

  
 D-3 

	 	(c)	 the foreign judgment must be final and conclusive and the decree must be final and unalterable in the court
which pronounces it. A judgment can be final and conclusive even if it is subject to appeal or even if an appeal is pending. Where however, the effect of lodging an appeal under the applicable law is to stay execution of the judgment, it is possible
that, in the meantime, the judgment should not be actionable in Ireland. It remains to be determined whether final judgment given in default of appearance is final and conclusive. 

Agent for Service of Process 
  

	 	1.17	 The appointment of Seagate Technology (US) Holdings, Inc. as agent for service of process in any suit or
proceeding based on or arising under any of the Transaction Documents would be recognised by the courts of Ireland. 

  
 D-4 

 EXHIBIT E 

FORM OF OPINION OF KATHERINE E. SCHUELKE 

To my knowledge there are no pending or threatened actions, suits or proceedings against or affecting the Company or any of its subsidiaries
or any of their respective properties other than proceedings fairly summarized in all material respects in the Time of Sale Memorandum and proceedings which are not likely to have a material adverse effect on the Company and its subsidiaries, taken
as a whole, or on the power or ability of the Company to perform its obligations under the Purchase Agreement, the Indentures, the Registration Rights Agreements or the Securities or to consummate the transactions contemplated by the Time of Sale
Memorandum. 

  
 E-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]